Advertisement Amakem receives EUR18m for ophthalmology drug development - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Amakem receives EUR18m for ophthalmology drug development

Amakem, a Belgium-based developer of new treatments for serious eye conditions, has received EUR18m fund to enhance its ophthalmology drug development program.

The funding has been awarded by its existing investors along with Forbion Capital Partners, Credit Agricole Private Equity and Vesalius BioCapital.

The company has progressed its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

In the preclinical studies, AMA0076 showed reduction in intraocular pressure (IOP).